Expanding the Boundaries of QbD
White Paper Jun 04, 2015
The last decade has seen a shift within the pharmaceutical industry towards a design space approach to development and manufacture, an agenda underpinned by ICHQ8, Q9 and Q10 and the concept of Quality by Design (QbD). However, because a design space approach naturally focuses attention on the areas of a project that are potentially the most vulnerable to failure it has broader value for risk management.
Within the pharmaceutical industry, those most confident and comfortable with QbD are beginning to extend its application beyond the product development path to, for example, the deployment of analytical equipment and associated method development, validation and transfer. The roots of the integrity of analytical data lie in the approach taken to the design and manufacture of the analytical instrument. Analytical instrument companies that align themselves with a QbD philosophy can therefore offer pharmaceutical customers the reassurance of closely similar working practices and products that meet the exacting standards of the industry.
In this article Paul Davies and Paul Kippax from Malvern Instruments examine how a QbD approach can inform analytical instrumentation design and manufacture, focusing on the benefits for those who go on to use the equipment. Examples from the development of the Mastersizer 3000 particle size analyzer demonstrate the practicalities.
Related White Papers
7 Key Factors When Considering a Benchtop X-ray DiffractometerWhite Paper
In this white paper, our marketing director of the America’s Kathy Macchiarola outlines the important decisions factors that are key requirements and help you select a benchtop system ideal for your situation and your needs.READ MORE
Supporting the Pharmaceutical Industry with 21 CFR Part 11 Compliance ReadinessWhite Paper
The purpose of this document is to describe how PANalytical systems support system owners meeting the requirements of the 21 CFR Part 11 regulations issued by the United States’ FDA.READ MORE
The Use of EDXRF for Pharmaceutical Material Elemental AnalysisWhite Paper
The recent changes to the United States Pharmacopeia (USP) regarding requirements for elemental impurity testing has peaked interest into new ways to perform this testing. Combining these new requirements with the introduction of USP chapter <735> X-ray fluorescence spectrometry1 permits a new alternate method for quantifying elemental impurities in pharmaceutical materials.READ MORE
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018